+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Collagen Vascular Diseases Market by Disease Indication, Therapy Type, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Collagen Vascular Diseases Market by Disease Indication, Therapy Type, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Collagen Vascular Diseases Market by Disease Indication, Therapy Type, End User, Route Of Administration, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 193 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924836
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Collagen Vascular Diseases Market grew from USD 32.21 billion in 2024 to USD 35.08 billion in 2025. It is expected to continue growing at a CAGR of 8.84%, reaching USD 53.56 billion by 2030.

Navigating the Complex Terrain of Collagen Vascular Diseases

Collagen vascular diseases, encompassing a broad spectrum of autoimmune disorders, continue to challenge clinicians and researchers alike due to their complex pathophysiology and varied clinical manifestations. These conditions, from rheumatoid arthritis to systemic sclerosis, demand multidimensional approaches that bridge breakthroughs in immunology with evolving therapeutic modalities. In this context, an in-depth examination of current diagnostic protocols, treatment paradigms, and patient management strategies is essential for stakeholders seeking to optimize outcomes and drive innovation. This executive summary lays the groundwork for understanding the intricate web of disease mechanisms, clinical unmet needs, and the competitive landscape shaping the trajectory of research and development in this dynamic field.

Unveiling Transformative Shifts in Treatment and Diagnostics

Over the past decade, the collagen vascular disease arena has experienced a seismic shift fueled by novel biologic platforms, precision medicine approaches, and advanced molecular diagnostics. The transition from broad-spectrum immunosuppression to targeted B cell depletion and interleukin blockade has redefined treatment algorithms, enabling more personalized strategies and improved safety profiles. At the same time, the integration of real-world evidence through digital health technologies and patient-reported outcomes has reshaped how therapeutic effectiveness and quality of life are measured. These transformative developments have not only accelerated drug pipelines but also fostered collaborative models that unite academic institutions, industry innovators, and regulatory bodies in pursuit of more robust clinical endpoints and accelerated approval pathways.

Assessing the Cumulative Impact of United States Tariffs 2025

In 2025, the introduction of elevated United States tariffs has introduced both challenges and opportunities across the collagen vascular therapeutic supply chain. While increased import duties on specialized biologics and small molecule precursors have driven up manufacturing and distribution costs, they have also stimulated domestic production investments and reshored key components of the critical supply chain. Several multinational companies have responded by negotiating long-term sourcing agreements and accelerating local facility expansions to offset duty burdens. Concurrently, a renewed emphasis on cost containment and pricing strategies has prompted payers to seek outcome-based contracting models, pushing manufacturers to demonstrate tangible health economic benefits of their therapies.

Illuminating Key Segmentation Insights Across Diverse Submarkets

The collagen vascular disease market reveals divergent growth trajectories when segmented by disease indication, therapy type, end user, route of administration, and distribution channel. Examination by disease indication shows that systemic lupus erythematosus remains a focal point of clinical trials, while vasculitis subtypes such as giant cell arteritis and ANCA associated vasculitis are garnering heightened attention due to recent regulatory approvals and robust unmet need. Analysis by therapy type underscores the continued ascendancy of interleukin inhibitors alongside an expanding pipeline of fusion proteins. Within end-user environments, hospitals maintain a dominant share of advanced therapeutic delivery, whereas research institutes are at the forefront of translational studies. Injectable formulations continue to outpace oral and topical routes, reflecting the biologics-heavy portfolio, and the evolution of distribution channels highlights the growing role of online pharmacies in improving patient access to specialty treatments.

Discovering Pivotal Regional Trends and Market Drivers

Regional dynamics in the collagen vascular disease marketplace underscore varied adoption curves and regulatory landscapes. In the Americas, market momentum is driven by strong payer support for precision therapies and an active pipeline of clinical studies. Europe, the Middle East, and Africa collectively exhibit a complex mosaic of reimbursement frameworks that both challenge and incentivize innovative pricing models, with key markets prioritizing health technology assessments. Meanwhile, Asia-Pacific is emerging as a hub for manufacturing scale-up and clinical trial enrollment, propelled by expanding patient populations and increasing government investments in biotechnology infrastructure. Each region’s blend of regulatory rigor, healthcare expenditure trends, and patient demographics shapes the competitive environment and dictates strategic entry approaches.

Examining Competitive Strategies of Leading Industry Players

Leading companies in the collagen vascular disease sphere are navigating a landscape defined by strategic alliances, accelerated regulatory filings, and an intensifying focus on next-generation therapeutics. Biopharma innovators with established anti-TNF and B cell therapies are broadening their pipelines to include novel interleukin targets and cell-based modalities. Additionally, specialty firms are carving out niches in orphan indications such as Takayasu’s arteritis, bolstered by breakthrough designations from global health authorities. Partnerships between small molecule developers and contract research organizations have expedited early phase trials for oral immunomodulators, while distributors are refining omnichannel strategies to streamline patient access. These corporate maneuvers, informed by competitive benchmarking and portfolio rationalization, are setting the stage for the next wave of market leadership.

Actionable Strategies to Propel Market Leadership

Industry leaders must adopt a multipronged approach to secure sustainable growth in the collagen vascular domain. First, prioritizing investment in precision diagnostics and biomarker development will advance patient stratification and enhance clinical trial success rates. Next, forging public-private collaborations can accelerate regulatory learning and ensure alignment on real-world evidence requirements. To mitigate tariff-related pressures, establishing regional manufacturing hubs and flexible supply networks will serve as critical risk management measures. In parallel, crafting value-based contracting models that link therapeutic outcomes to reimbursement will resonate with increasingly cost-conscious payers. Finally, integrating digital health platforms to capture patient-reported data will not only support long-term safety monitoring but also differentiate product offerings in a crowded market.

Ensuring Rigor Through a Robust Research Methodology

This analysis is underpinned by a mixed-method research framework combining primary interviews with key opinion leaders, rigorous secondary data compilation from peer-reviewed journals and regulatory filings, and quantitative modeling of historical market trends. In-depth consultations with clinical experts and payers provided firsthand insights into evolving treatment paradigms and reimbursement dynamics. Proprietary databases were leveraged to map clinical trial activity, product launch timelines, and patent landscapes. Finally, regional regulatory environments were scrutinized to assess policy impacts, with findings cross-validated through triangulation of multiple data sources to ensure reliability and comprehensiveness.

Concluding Reflections on Market Dynamics and Opportunities

The collagen vascular disease market stands at an inflection point, defined by breakthroughs in targeted therapies, evolving reimbursement models, and regional shifts in manufacturing footprints. Stakeholders equipped with an integrated understanding of disease-specific drivers, tariff implications, and competitive tactics will be best positioned to capitalize on emerging opportunities. Looking ahead, continued collaboration across sectors and investment in precision medicine will accelerate the delivery of transformative treatments to patients worldwide, reshaping the standard of care for these complex autoimmune conditions.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Disease Indication
    • Dermatomyositis
    • Rheumatoid Arthritis
    • Sjogren's Syndrome
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
      • Large Vessel Vasculitis
        • Giant Cell Arteritis
        • Takayasu's Arteritis
      • Medium Vessel Vasculitis
        • Kawasaki Disease
        • Polyarteritis Nodosa
      • Small Vessel Vasculitis
        • ANCA Associated Vasculitis
        • Cryoglobulinemic Vasculitis
        • IgA Vasculitis
  • Therapy Type
    • Biologics
      • Anti-TNF Agents
      • B Cell Depleting Therapies
      • Fusion Proteins
      • Interleukin Inhibitors
    • Immunosuppressants
    • Small Molecule Drugs
    • Steroids
  • End User
    • Clinics
    • Hospitals
    • Research Institutes
  • Route Of Administration
    • Injectable
    • Oral
    • Topical
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Roche Holding AG
  • Novartis AG
  • Johnson & Johnson
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • UCB S.A.
  • Sanofi S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Collagen Vascular Diseases Market, by Disease Indication
8.1. Introduction
8.2. Dermatomyositis
8.3. Rheumatoid Arthritis
8.4. Sjogren's Syndrome
8.5. Systemic Lupus Erythematosus
8.6. Systemic Sclerosis
8.7. Vasculitis
8.7.1. Large Vessel Vasculitis
8.7.1.1. Giant Cell Arteritis
8.7.1.2. Takayasu's Arteritis
8.7.2. Medium Vessel Vasculitis
8.7.2.1. Kawasaki Disease
8.7.2.2. Polyarteritis Nodosa
8.7.3. Small Vessel Vasculitis
8.7.3.1. ANCA Associated Vasculitis
8.7.3.2. Cryoglobulinemic Vasculitis
8.7.3.3. IgA Vasculitis
9. Collagen Vascular Diseases Market, by Therapy Type
9.1. Introduction
9.2. Biologics
9.2.1. Anti-TNF Agents
9.2.2. B Cell Depleting Therapies
9.2.3. Fusion Proteins
9.2.4. Interleukin Inhibitors
9.3. Immunosuppressants
9.4. Small Molecule Drugs
9.5. Steroids
10. Collagen Vascular Diseases Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Research Institutes
11. Collagen Vascular Diseases Market, by Route Of Administration
11.1. Introduction
11.2. Injectable
11.3. Oral
11.4. Topical
12. Collagen Vascular Diseases Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Collagen Vascular Diseases Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Collagen Vascular Diseases Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Collagen Vascular Diseases Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Roche Holding AG
16.3.3. Novartis AG
16.3.4. Johnson & Johnson
16.3.5. Pfizer Inc.
16.3.6. Bristol-Myers Squibb Company
16.3.7. Eli Lilly and Company
16.3.8. GlaxoSmithKline plc
16.3.9. UCB S.A.
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. COLLAGEN VASCULAR DISEASES MARKET MULTI-CURRENCY
FIGURE 2. COLLAGEN VASCULAR DISEASES MARKET MULTI-LANGUAGE
FIGURE 3. COLLAGEN VASCULAR DISEASES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. COLLAGEN VASCULAR DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SJOGREN'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY GIANT CELL ARTERITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TAKAYASU'S ARTERITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANCA ASSOCIATED VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY CRYOGLOBULINEMIC VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IGA VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANTI-TNF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY B CELL DEPLETING THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 73. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 74. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 75. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 76. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 133. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 134. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 136. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 139. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 143. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 144. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 146. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 164. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 165. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 166. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 167. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 168. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 169. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 173. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 174. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 176. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 177. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 179. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 213. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 214. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 216. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 217. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 218. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 219. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 233. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 234. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 235. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 236. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 237. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 238. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 239. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 243. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 248. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 249. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 273. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 274. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 276. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 278. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 279. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 283. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 284. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 286. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 287. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 288. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 289. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 303. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, 2018-2030 (USD MILLION)
TABLE 304. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY LARGE VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 305. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDIUM VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SMALL VESSEL VASCULITIS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY THERA

Companies Mentioned

The companies profiled in this Collagen Vascular Diseases market report include:
  • AbbVie Inc.
  • Roche Holding AG
  • Novartis AG
  • Johnson & Johnson
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • UCB S.A.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 35.08 Billion
Forecasted Market Value ( USD ) by 2030 $ 53.56 Billion
Compound Annual Growth Rate8.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Scleroderma - Pipeline Insight, 2025 - Product Image

Scleroderma - Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Behcet Disease Drug Market by Therapeutic Class, Product Type, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Behcet Disease Drug Market by Therapeutic Class, Product Type, Route Of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025 - Product Image

Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025

  • Clinical Trials
  • 75 Pages
  • Global
From
Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type [Type 1 Collagen and Hyaluronic Acid], End User, and Country - Product Image

Europe Intra-Articular Injection for Osteoarticular Infiltrations Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type [Type 1 Collagen and Hyaluronic Acid], End User, and Country

  • Report
  • 92 Pages
  • Europe
From

About the Collagen Vascular Disease Drug Market

Collagen Vascular Disease (CVD) Drug is a type of drug used to treat immune disorders. These drugs are used to reduce inflammation and suppress the immune system, which can help reduce the symptoms of CVD. They can also help to reduce the risk of complications from CVD, such as organ damage. CVD drugs are typically prescribed by a doctor and can be taken orally or intravenously. Common CVD drugs include corticosteroids, immunosuppressants, and biologics. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunosuppressants are used to reduce the activity of the immune system. Biologics are used to target specific parts of the immune system and can be used to treat specific conditions. The CVD Drug market is a growing market, with many companies offering a variety of drugs to treat CVD. Some of the major companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.